| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C22H30ClNO4S |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
ONO-8711 is a potent, selective competitive antagonist of the EP1 receptor, with Ki values of 0.6 nM for human EP1 and 1.7 nM for mouse EP1. In mouse models of colon, breast, and oral cancer, it effectively reduces tumor incidence and multiplicity[1]. It has a molecular formula of C22H30ClNO4S and a molecular weight of 440.00 g/mol.
Physical & Chemical Properties
| CAS Number | 216158-34-8 |
|---|---|
| Molecular Formula | C22H30ClNO4S |
| Molecular Weight | 440.00 g/mol |
| SMILES | O=C(O)CCC/C=C\[C@H]1C(CC2)CCC2[C@@H]1CNS(=O)(C3=CC=C(Cl)C=C3C)=O |
| Target | EP |
| Signaling Pathway | GPCR/G Protein |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
ONO-8711 (10 and 30 μM; 30 min) blocks sulprostone-induced contractions in human pulmonary veins in a non-competitive manner[2]. The PGE2-induced rise in cytosolic Ca2+ concentration is inhibited by ONO-8711 at the mouse, human, and rat receptors, with IC50s of 0.21 μM, 0.05 μM, and 0.22 μM, respectively[3].
In Vivo
ONO-8711 (400 or 800 p.p.m.; p.o.; for 20 weeks) lowers cancer incidence and delays the onset of breast tumors[3].
| Animal Model | Female Sprague-Dawley rats (induced breast cancer by gavage of 85 mg/kg PhIP 4 times for 2 weeks) |
|---|---|
| Dosage | 400 or 800 p.p.m. |
| Administration | p.o.; for 20 weeks |
| Result | Did not induce any symptoms of toxicity at 800 p.p.m. Delayed occurrence of breast tumors for 2 or 4 weeks at 400 or 800 p.p.m., respectively. Significantly suppressed cancer incidence compared with the control diet group at 800 p.p.m. (56% versus 79%, P < 0.05). |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
